长春瑞滨联合卡培他滨对蒽环类和紫杉类药物耐药的晚期乳腺癌疗效观察

目的观察长春瑞滨联合卡培他滨对蒽环类和紫杉类药物耐药的晚期乳腺癌患者的疗效和不良反应。方法32例晚期乳腺癌患者经长春瑞滨25mg/m^2，静脉滴注，d1、8；卡培他滨2000mg/（m^2·d），早晚2次，餐后30 min口服，d1-14，21d为1个周期，每例患者至少接受2个周期化疗或至疾病进展。结果32例患者共完成161个周期化疗，中位化疗5个周期。所有患者均可评价疗效和不良反应，其中完全缓解（CR）1例，部分缓解（PR）9例，疾病稳定（SD）13例，疾病进展（PD）9例。总有效率（CR＋PR）31.2%，疾病控制率（DCR）71.9%，中位无进展生存期（TTP）8.3个月，1、2年生存率分别为66.9%和38.4%。不良反应主要为骨髓抑制、手足综合征及静脉炎，没有发生治疗相关性死亡。结论长春瑞滨联合卡培他滨方案是治疗对蒽环类和紫杉类药物耐药的晚期乳腺癌患者的有效方案，不良反应可以耐受。

Vinorelbine combined with capecitabine for advanced breast cancer patients with anthracycline and taxane failure

Objective To evaluate the clinical efficacy and tolerance of vinorelbine with capecitabine for advanced breast cancer patients with anthracycline and taxane failure. Methods Thirty- two patients with anthracycline- and taxane- failure metastatic breast cancer were enrol ed in the study. Al patients were given 25mg/m^2 of vinorelbine on d1 and d8, combined with 2 000mg/m^2 of capecitabine daily from d1 to d14. The combined chemotherapy was repeated every 21d as one cycle. Patients received a minimal chemotherapy of two cycles or until disease progression. Results Al the 32 patients completed total 161 chemotherapy cycles with a median of 5 per patient. Adverse events and clinical efficacy were evaluated on all 32 patients. There were complete remission （CR） in 1 patient, partial remission （PR） in 9, stable disease （SD） in 13 and progression of disease （PD） in 9. The overal response rate （CR＋PR） was 31.2%and the disease control rate （DCR） was 71.9%. The median time to progres-sion （TTP） was 8.3 months, 1- year and two- year survival rate was 66.9%and 38.4%, respectively. The most commonly observed adverse events were bone marrow depression and hand- foot syndrome and angeitis. No mortality occurred during the treat-ment. Conclusion Vinorelbine combined with capecitabine is an effective and safe chemotherapeutic regimen for anthracy-cline- and taxane- failure metastatic breast cancer and the adverse reactions are wel tolerated.